Clinical Trial

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2023 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-07-28.
Trial Details
NCT Number NCT05479240
Lead Sponsor Fujian Cancer Hospital
Conditions Immunotherapy
Enrollment 94 participants
Start Date 2023-09-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-18